FDA Grants Orphan Drug Designation to AUM302 for Neuroblastoma
A global clinical-stage biotech company, AUM Biosciences, focused on discovering and developing precision oncology therapeutics, declared that the U.S. FDA has permitted Orphan Drug Designation for AUM302. For the treatment of neuroblastoma, AUM302 is a potential first-in-class oral kinase inhibitor that not only targets PI3K but also important resistance mechanisms like PIM and mTOR.
Preclinical studies of AUM302 have showed that complementing conventional chemotherapy treatment with PIM/PI3K/mTOR inhibition can improve clinical outcomes in children having high-risk of neuroblastoma and inhibit canc...
